1.Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial.
Jingyao CHEN ; Fei DONG ; Wei CHEN ; Xuguang SUN ; Yingping DENG ; Jing HONG ; Mingchang ZHANG ; Wenzhao YANG ; Zuguo LIU ; Lixin XIE
Chinese Medical Journal 2014;127(13):2407-2412
BACKGROUNDDry eye is a multifactorial disease of the tears and the ocular surface. This study aimed to investigate the clinical efficacy of a non-steroidal anti-inflammatory drug, pranoprofen, in the treatment of dry eye.
METHODSIt is a prospective, multi-center, randomized, controlled, parallel group study. One hundred and fifteen patients with mild to moderate dry eye disease (55-60 in each treatment group) participated in this multi-center study. Patients were randomly administered with eyedrops containing 0.1% pranoprofen (PRA) plus 0.1% sodium hyaluronate (SH) or SH only, three times daily for 28 days, followed by a 1-week after treatment observation. Dry eye symptom score (DESS), fluorescein corneal staining (FLCS), tear break-up time (TBUT), and Shirmer 1 tear test (ST1, without anesthesia) were evaluated or conducted before treatment and at each study visit. Conjunctival impression cytology was taken from the patients treated with PRA plus SH before and after treatment and real-time polymerase chain reaction (RT-PCR) was performed to detect the changes of human leukocyte antigen DR (HLA-DR) and intercellular adhesion molecule 1 (ICAM-1).
RESULTSPatients treated with PRA plus SH showed gradual improvements of DESS, FLCS, and TBUT. Between-group comparisons of FLCS and TBUT have statistically significant differences from day 14. Good tolerance with no severe adverse events was found in both groups. Patients treated with PRA plus SH had a reduced expression level of HLA-DR and were statistically different after 28 days of therapy.
CONCLUSIONSThe application of PRA at a dose of 0.1% was well tolerated and benefited to the patients with mild to moderate dry eye disease. The underlying mechanism of its efficacy may be associated with the reduction of inflammatory factors of conjunctival epithelial cells.
Adult ; Benzopyrans ; therapeutic use ; Dry Eye Syndromes ; drug therapy ; Humans ; Middle Aged ; Ophthalmic Solutions ; therapeutic use ; Propionates ; therapeutic use
2.Inflammatory Cytokine and Osmolarity Changes in the Tears of Dry Eye Patients Treated with Topical 1% Methylprednisolone.
Ji Hwan LEE ; Kyung MIN ; Se Kyung KIM ; Eung Kweon KIM ; Tae Im KIM
Yonsei Medical Journal 2014;55(1):203-208
PURPOSE: To evaluate changes in clinical outcomes, inflammatory cytokine levels, and tear osmolarity in the tears of patients with moderate to severe dry eye syndrome before and after the application of topical 1% methylprednisolone. MATERIALS AND METHODS: Thirty-two patients with moderate to severe dry eye unresponsive to previous aqueous enhancement therapy were enrolled. Five patients were lost to follow up, and twenty-seven patients were eligible for analysis. Patients were instructed to apply topical 1% methylprednisolone four times per day, as well as to continue applying their current therapy of preservative-free 0.1% sodium hyaluronate four times per day. Corneal and conjunctival staining scores, tear film breakup time (TFBUT), Schirmer test, and tear osmolarity were assessed at baseline, 4 weeks, and 8 weeks. Tear samples were collected at every visit for cytokine analysis. RESULTS: Corneal and conjunctival staining scores and TFBUT showed significant improvement at 4 (p<0.001, <0.001, <0.001 respectively) and 8 (p<0.001, <0.001, <0.001 respectively) weeks. Tear osmolarity decreased significantly at 8 weeks (p=0.008). Interleukin (IL)-1beta, IL-8, and monocyte chemoattractant protein-1 were significantly decreased at 8 weeks compared with those at baseline (p=0.041, 0.001, 0.008 respectively). CONCLUSION: Short-term treatment with topical 1% methylprednisolone not only improved clinical outcomes, but also decreased tear osmolarity and cytokine levels. By measuring the changes in cytokine levels and tear osmolarity, we could objectively evaluate the anti-inflammatory effects of topical methylprednisolone applied in the treatment of patients with moderate to severe dry eye syndrome.
Adult
;
Aged
;
Cytokines/*metabolism
;
Dry Eye Syndromes/*drug therapy/metabolism
;
Female
;
Humans
;
Male
;
Methylprednisolone/administration & dosage/*therapeutic use
;
Middle Aged
;
Osmolar Concentration
;
Prospective Studies
;
Tears/*chemistry/*metabolism
3.A clinical study of the efficacy of topical corticosteroids on dry eye.
Chong-qing YANG ; Wen SUN ; Yang-shun GU
Journal of Zhejiang University. Science. B 2006;7(8):675-678
OBJECTIVETo evaluate the effect of topical corticosteroid for treatment of moderate or severe dry eye.
METHODSSixty eyes of 30 patients with moderate or severe dry eye, who were not sensitive to artificial tears, were treated with 0.1% fluorometholone eye drops. Subjective symptom and objective tests were used to evaluate the efficacy of treatment before and after application of 0.1% fluorometholone eye drops for 1 week and 1 month. Side effects were also evaluated.
RESULTSAfter 1 week of treatment, subjective symptoms were improved in all dry eye patients; objective tests were improved in all dry eye patients 1 month after treatment, and the difference was significant.
CONCLUSIONTopical corticosteroid drops can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye.
Administration, Topical ; Adult ; Dry Eye Syndromes ; drug therapy ; Female ; Fluorometholone ; administration & dosage ; adverse effects ; Glucocorticoids ; administration & dosage ; Humans ; Male ; Middle Aged
4.Analysis of Clinical Features and Prognostic Factor Analysis of Orbital and Adnexal Lymphoma.
Sang Jun LEE ; Jae Ho JUNG ; Hee Young CHOI
Journal of the Korean Ophthalmological Society 2013;54(1):12-18
PURPOSE: To study the clinical features, pathophysiologic and radiologic characteristics, and prognostic factors in patients with orbital and adnexal lymphoma. METHODS: The medical records of patients who were diagnosed with orbital and adnexal lymphoma, and patients who were treated and observed, were retrospectively reviewed. Information regarding age, sex, initial symptoms and signs when visiting the hospital, mass location and features, histology and staging, response to treatment and side effects, and prognosis were collected. RESULTS: Fifty-four patients, with an equal number of men and women, were diagnosed with orbital and adnexal lymphoma. The average age was 50.9 years (14 to 82 years). The main symptom was orbital swelling, and the main site was conjunctiva. Histologically, Mucosa-Associated Lymphoid Tissue (MALT) lymphoma was the most observed. The major ocular complication was dry eye syndrome, which showed good response with ophthalmic treatment. Radiologic features did not have prognostic relevance. CONCLUSIONS: Most orbital and adnexal lymphomas were MALT lymphomas. Proper therapy according to stage can result in a good response and remission. In the present study, the therapy complications were well-controlled with medical treatment, and radiologic features of a mass could not be considered as a prognostic factor.
Conjunctiva
;
Drug Therapy
;
Dry Eye Syndromes
;
Factor Analysis, Statistical*
;
Female
;
Humans
;
Lymphoid Tissue
;
Lymphoma*
;
Lymphoma, B-Cell, Marginal Zone
;
Male
;
Medical Records
;
Orbit*
;
Prognosis
;
Radiotherapy
;
Retrospective Studies
5.A comparative assessment of the efficacy of carbomer gel and carboxymethyl cellulose containing artificial tears in dry eyes.
Qing, XIAO ; Yanhua, HU ; Fei, CHEN ; Xiaomin, CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2008;28(5):592-5
The present study aimed to compare the clinical efficacy of a 0.4% carbomer gel and 1% carboxymethyl cellulose (CMC) containing artificial tears in treatment of dry eye patients. Sixty subjects with mean age of 45.89 years who had symptoms and signs of dry eye were enrolled in this prospective, investigator-masked and stratified random sampling study. The subjects were divided into two parallel groups with 30 subjects (60 eyes) in each group. One group received carbomer gel, and the other group received 1% CMC containing artificial tears. Subjects received the drops 3 to 4 times or more per day for 3 months. At the first visit time, the precorneal residence time of these two drops was measured. The efficacy was assessed by comparing the subjective symptoms (ocular dryness, foreign body sensation, burning sensation and pain), and the objective test results of tears breakup time, Schirmer's test and corneal fluorescein staining prior to the study and after the treatment. As a result, the ocular residence time of carbomer gel was significantly longer than that of 1% CMC (P<0.001). Most of the primary subjective symptoms and objective test results were improved after treatment in both carbomer gel group and 1% CMC group. As to the improvement of each symptom and objective test result, carbomer gel was more effective than 1% CMC group (P<0.01). In conclusion, carbomer gel had longer precorneal residence time and was more effective than 1% CMC in the treatment of patients with dry eyes.
Acrylic Resins/*administration & dosage
;
Carboxymethylcellulose Sodium/*administration & dosage
;
Dry Eye Syndromes/*drug therapy
;
Gels/*administration & dosage
;
Ophthalmic Solutions/administration & dosage
;
Prospective Studies
6.Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications.
Xing LIU ; Fen-Fen YU ; Yi-Min ZHONG ; Xin-Xing GUO ; Zhen MAO
Chinese Medical Journal 2015;128(18):2444-2449
BACKGROUNDLong-term use of benzalkonium chloride (BAC)-preserved drugs is often associated with ocular surface toxicity. Ocular surface symptoms had a substantial impact on the glaucoma patients' quality of life and compliance. This study aimed to investigate the effects of sodium hyaluronate (SH) on ocular surface toxicity induced by BAC-preserved anti-glaucoma medications treatment.
METHODSFifty-eight patients (101 eyes), who received topical BAC-preserved anti-glaucoma medications treatment and met the severe dry eye criteria, were included in the analysis. All patients were maintained the original topical anti-glaucoma treatment. In the SH-treated group (56 eyes), unpreserved 0.3% SH eye drops were administered with 3 times daily for 90 days. In the control group (55 eyes), phosphate-buffered saline were administered with 3 times daily for 90 days. Ocular Surface Disease Index (OSDI) questionnaire, break-up time (BUT) test, corneal fluorescein staining, corneal and conjunctival rose Bengal staining, Schirmer test, and conjunctiva impression cytology were performed sequentially on days 0 and 91.
RESULTSCompared with the control group, SH-treated group showed decrease in OSDI scores (Kruskal-Wallis test: H = 38.668, P < 0.001), fluorescein and rose Bengal scores (Wilcoxon signed-ranks test: z = -3.843, P < 0.001, and z = -3.508, P < 0.001, respectively), increase in tear film BUT (t-test: t = -10.994, P < 0.001) and aqueous tear production (t-test: t = -10.328, P < 0.001) on day 91. The goblet cell density was increased (t-test: t = -9.981, P < 0.001), and the morphology of the conjunctival epithelium were also improved after SH treatment.
CONCLUSIONSSH significantly improved both symptoms and signs of ocular surface damage in patients with BAC-preserved anti-glaucoma medications treatment. SH could be proposed as a new attempt to reduce ocular surface toxicity, and alleviate symptoms of ocular surface damage in BAC-preserved anti-glaucoma medications treatment.
Adolescent ; Adult ; Aged ; Benzalkonium Compounds ; adverse effects ; Dry Eye Syndromes ; chemically induced ; prevention & control ; Eye ; drug effects ; Eye Injuries ; chemically induced ; prevention & control ; Female ; Glaucoma ; drug therapy ; Humans ; Hyaluronic Acid ; therapeutic use ; Male ; Middle Aged ; Young Adult
7.The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery.
Yeon Woong CHUNG ; Tae Hoon OH ; Sung Kun CHUNG
Korean Journal of Ophthalmology 2013;27(3):167-171
PURPOSE: To evaluate the effectiveness of cyclosporine 0.05% for dry eye after cataract surgery. METHODS: Thirty-two newly diagnosed patients with dry eye syndrome 1 week after cataract surgery received a twice-daily treatment of cyclosporine 0.05% for one eye and normal saline 0.9% for the other. Disease severity was measured at 2 weeks, 1 month, 2 months, and 3 months by Schirmer test I (ST-I), tear film break-up time (tBUT), corneal temperature and dry eye symptom questionnaire (Ocular Surface Disease Index). RESULTS: Both groups increased in ST-I and tBUT over time. ST-I in the cyclosporine 0.05% group showed a significant increase at 3 months and tBUT in the cyclosporine 0.05% group showed an increase at 2 and 3 months. The dry eye symptom score was significantly reduced in the cyclosporine 0.05% group. CONCLUSIONS: Cyclosporine 0.05% can also be an effective treatment for dry eye after cataract surgery.
Aged
;
Aged, 80 and over
;
*Cataract Extraction
;
Cyclosporine/*administration & dosage
;
Dry Eye Syndromes/*drug therapy
;
Female
;
Humans
;
Immunosuppressive Agents/administration & dosage
;
Male
;
Middle Aged
;
Ophthalmic Solutions/*administration & dosage
;
Postoperative Complications/*drug therapy
;
Treatment Outcome
8.The Effect of TNF-α Blocker HL036337 and Its Best Concentration to Inhibit Dry Eye Inflammation.
Wungrak CHOI ; Hyemi NOH ; Areum YEO ; Hanmil JANG ; Hyea Kyung AHN ; Yeon Jung SONG ; Hyung Keun LEE
Korean Journal of Ophthalmology 2016;30(4):302-308
PURPOSE: Dry eye syndrome is commonly thought of as an inflammatory disease, and we have previously presented data showing the effectiveness of topical TNF-α blocker agents for the treatment of this condition. The purpose of this study was to investigate the effectiveness of the TNF-α blocking agent HL036337 compared to cyclosporine A for the treatment of dry eye induced inflammation in order to establish whether HL036337 represents a more effective method for suppressing inflammation. The efficacy of HL036337 and cyclosporine A was determined using an experimental murine dry eye model. METHODS: The TNF-α blocker HL036337 is a modified form of TNF receptor I. Using dry eye induced C57BL/6 mice (n = 45), corneal erosion was measured at day 4 and 7 after topical treatment with cyclosporine A or HL036337. To determine the effective treatment dose, 0.25, 0.5, 1, 2.5, and 5 mg/mL of HL036337 were topically administered twice per day to dry eye induced murine corneas for 1 week. RESULTS: The optimal concentration of the TNF-α blocker HL036337 for treatment of dry eye induced corneal erosion was determined to be 1 mg/mL. Dry eye induced corneal erosion was improved after 1 week with topically applied cyclosporine A and HL036337 at 1 mg/mL. CONCLUSIONS: HL036337 administered topically at 1 mg/mL effectively improved corneal erosion induced by dry eye. This finding may also suggest that inhibition of TNF-α can improve dry eye syndrome.
Animals
;
Cornea/diagnostic imaging
;
Disease Models, Animal
;
Dose-Response Relationship, Drug
;
Dry Eye Syndromes/diagnosis/*drug therapy
;
Female
;
Mice
;
Mice, Inbred C57BL
;
Microscopy, Acoustic
;
Ophthalmic Solutions/administration & dosage
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
9.Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance Study.
Yong Soo BYUN ; Chang Rae RHO ; Kyungjin CHO ; Jin A CHOI ; Kyung Sun NA ; Choun Ki JOO
Korean Journal of Ophthalmology 2011;25(6):369-374
PURPOSE: To assess the effectiveness and tolerability of cyclosporine ophthalmic emulsion (CsA) 0.05% in patients with moderate to severe dry eye disease in Korea. METHODS: This was a prospective, multicenter, open-label, surveillance study of 392 Korean patients with moderate to severe dry eye disease who were treated with CsA 0.05% for three months. An assessment of effectiveness was performed at baseline, and after 1, 2, and 3 months. The primary effectiveness outcomes were changes in ocular symptoms and Schirmer score. The secondary effectiveness outcomes were a change in conjunctival staining, use of artificial tears, global evaluation of treatment, and patient satisfaction. The primary safety outcome was the incidence and nature of adverse events. RESULTS: A total of 362 patients completed the study. After three months, all ocular symptom scores were significantly reduced compared to the baseline values, while the Schirmer scores were significantly increased relative to baseline (p < 0.0001). After three months, there were significant reductions from baseline in conjunctival staining (p < 0.01) and use of artificial tears (p < 0.0001). According to clinicians' global evaluations, most patients (>50%) experienced at least a 25% to 50% improvement in symptoms from baseline at each follow-up visit. The majority of patients (72.0%) were satisfied with the treatment results, and 57.2% reported having no or mild symptoms after treatment. The most common adverse events were ocular pain (11.0%). CONCLUSIONS: Our findings indicate that CsA 0.05% is an effective and tolerable treatment for dry eye disease in Korean clinical practice.
Cyclosporine/*administration & dosage/adverse effects
;
Dry Eye Syndromes/*drug therapy/epidemiology
;
Emulsions
;
Female
;
Follow-Up Studies
;
Humans
;
Immunosuppressive Agents/*administration & dosage/adverse effects
;
Male
;
Middle Aged
;
Population Surveillance
;
Prospective Studies
;
Republic of Korea/epidemiology
;
Treatment Outcome
10.Preliminary Effects of Oral Uridine on the Ocular Surface in Dry Eye Patients.
Ki Cheol CHANG ; Joo Youn OH ; Youn Seok IN ; Mee Kum KIM ; Ki Cheul SHIN ; Won Ryang WEE ; Jin Hak LEE ; Myung Gyu PARK
Journal of Korean Medical Science 2009;24(4):701-707
We designed a randomized, double blinded, 3-months controlled prospective clinical study to investigate effects of oral uridine on the ocular surface in dry eye patients. Twenty-seven patients who diagnosed as dry eye with lower than 5 mm of wetting in the Schirmer strip, with corneal epithelial erosion and who completely followed-up till 3 months were enrolled. Corneal-conjunctival fluorescein staining, non-anesthetic Schirmer test, impression cytology, and Ocular Surface Disease Index (OSDI) were evaluated in the experimental and placebo groups at the baseline, 1 and 3 months after start of medication in a double blinded manner. Fluorescein stain score of the cornea was markedly decreased in oral uridine group compared to the placebo group at 3 months after medication (P=0.032, Mann-Whitney U test). The Schirmer wetting score for the oral uridine group was significantly increased (P=0.001, Wilcoxon signed rank test) at 3 months and its difference between two groups was statistically significant (P=0.030, Mann-Whitney U test). OSDI scores were significantly decreased at 1 and 3 months in treatment group. Oral uridine is effective in treatment of dry eyes.
Administration, Oral
;
Adolescent
;
Adult
;
Aged
;
Conjunctiva/pathology
;
Cornea/pathology
;
Double-Blind Method
;
Dry Eye Syndromes/*drug therapy
;
Female
;
Fluorescent Dyes/pharmacology
;
Humans
;
Male
;
Middle Aged
;
Severity of Illness Index
;
Uridine/administration & dosage/*therapeutic use